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Abstract
Synthetic peroxisome proliferator-activated receptor (PPAR) agonists are used to treat dyslipidemia and insulin resistance. In
this study, we examined molecular mechanisms that explain differential effects of a PPARa agonist (fenofibrate) and a PPARc
agonist (rosiglitazone) on macrophages during obesity-induced atherogenesis. Twelve-week-old mice with combined leptin
and LDL-receptor deficiency (DKO) were treated with fenofibrate, rosiglitazone or placebo for 12 weeks. Only rosiglitazone
improved adipocyte function, restored insulin sensitivity, and inhibited atherosclerosis by decreasing lipid-loaded
macrophages. In addition, it increased interleukin-1 receptor-associated kinase-3 (Irak3) and decreased monocyte
chemoattractant protein-1 (Mcp1) expressions, indicative of a switch from M1 to M2 macrophages. The differences between
fenofibrate and rosiglitazone were independent of Pparc expression. In bone marrow-derived macrophages (BMDM), we
identified the rosiglitazone-associated increase in adiponectin as cause of the increase in Irak3. Interestingly, the deletion of
Irak3 in BMDM (IRAK32/2 BMDM) resulted in activation of the canonical NFkB signaling pathway and increased Mcp1
protein secretion. Rosiglitazone could not decrease the elevated Mcp1 secretion in IRAK32/2 BMDM directly and fenofibrate
even increased the secretion, possibly due to increased mitochondrial reactive oxygen species production. Furthermore,
aortic extracts of high-fat insulin-resistant LDL-receptor deficient mice, with lower adiponectin and Irak3 and higher Mcp1,
showed accelerated atherosclerosis. In aggregate, our results emphasize an interaction between PPAR agonist-mediated
increase in adiponectin and macrophage-associated Irak3 in the protection against atherosclerosis by PPAR agonists.
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Introduction
Low-grade chronic inflammation is associated with obesity and
obesity-induced metabolic disorders such as insulin resistance, type
2 diabetes, the metabolic syndrome and atherosclerosis [1,2]. The
recruitment of monocytes and differentiation and polarization to
classically activated pro-inflammatory M1 macrophages instead of
anti-inflammatory M2 macrophages, have been causally linked to
the development of adipose tissue dysfunction, the metabolic
syndrome and atherosclerosis [3]. The monocyte chemoattractant
protein-1 (Mcp1, also known as chemokine (C-C motif) ligand-2,
Ccl2), a marker of M1 macrophages, increases macrophage
infiltration, inflammation and insulin resistance in transgenic mice.
Conversely, disruption of Mcp1 or its receptor Ccr2 impairs
migration of macrophages thereby lowering adipose tissue in-
flammation and improving insulin sensitivity [4]. It is also
recognized that maladaptive production of various adipocytokines
(e.g. adiponectin, resistin, visfatin, and leptin) and pro-inflamma-
tory cytokines, such as tumor necrosis factor-a (TNFa) and
interleukin (IL)-6, are implicated in the development of obesity-
related systemic inflammation and insulin resistance. In particular,
the blood levels of adiponectin are significantly lower in obese
individuals and have been associated with metabolic inflamma-
tion, insulin resistance and the development of cardiovascular
disease [5]. The protective effect of adiponectin has mainly been
attributed to its anti-inflammatory action [6]. Interestingly,
interleukin-1 receptor-associated kinase-3 (IRAK3; also referred
to as IRAK-M), a kinase deficient member of the IRAK family
and an important negative regulator of toll-like receptor/nuclear
factor kB (NFkB) signaling [7,8], is a major mediator of globular
adiponectin-induced endotoxin tolerance in macrophages [9].
Recently, we showed that decreased expression of IRAK3 in
monocytes of obese patients is associated with a high prevalence of
metabolic syndrome; weight loss results in an increase in IRAK3
that is associated with decreased systemic inflammation [10].
Several clinical trials support the use of peroxisome proliferator-
activated receptor (PPAR) agonists to treat dyslipidemia and
insulin resistance in obesity and type 2 diabetes. PPARa agonists
such as fenofibrate regulate lipoprotein metabolism [11]. PPARc
agonists such as rosiglitazone reduce blood glucose levels in
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patients with type 2 diabetes [12]. Recent data also suggest critical
roles of PPAR agonists in inhibiting vascular inflammation and
atherosclerosis [13–15]. However, it remains to be determined if
molecular mechanisms that confer their vascular protection are
identical for PPARa and PPARc agonists.
In the present study, we aimed to analyze the consequences of
PPARa and PPARc agonist treatment on macrophage activation
in relation to atherogenesis using mice with combined leptin (Ob/
Ob) and LDL-receptor deficiency (double knockout [DKO] mice).
These mice are characterized by morbid obesity, dyslipidemia,
glucose intolerance and insulin resistance, and accelerated
atherosclerosis [16,17]. Atherosclerotic lesions cover 20% of total
area of the thoracic abdominal aorta in double-mutant mice
compared with 3.5% in LDL-receptor deficient mice. Ob/Ob
mice have no detectable lesions. Higher macrophage homing is
detected prior to increase in plaque volumes in the aortic root of
DKO mice [16]. In intra-abdominal adipose tissues of DKO mice,
Pparc expression is lower than in LDL-receptor deficient and Ob/
Ob mice, and Ppara expression is lower than in LDL-receptor
deficient mice. Weight loss increases Ppara and Pparc, associated
with a decrease in atherosclerosis [17]. Because DKO mice, in
contrast to single KO mice, are characterized by decreases in
Ppara and Pparc and accelerated atherosclerosis, we selected
DKO mice to investigate the effect of fenofibrate and rosiglita-
zone. We found that rosiglitazone treatment in contrast to
fenofibrate increases systemic adiponectin levels and Irak3
expression, resulting in decreased expression of Mcp1 in athero-
sclerotic plaques. Moreover, the presence of Irak3 in macrophages
is necessary for the indirect Mcp1-reducing effects of PPAR
agonists. Because defective leptin signaling was found to modulate
inflammation and atherosclerosis [18], we also studied the relation
between low adiponectin (Adipoq) and Irak3 expression in aortic
extracts of high-fat and insulin resistant LDL-receptor deficient
mice characterized by high plasma leptin levels.
Materials and Methods
Experimental Protocol of Animal Studies
Animal experiments conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health. They were approved by the Institutional
Animal Care and Research Advisory Committee of the KU
Leuven (Permit Number: P087/2007). Breeding and genotyping of
DKO mice, on the C57BL/6 J background, were performed as
previously described [16,17]. Figure 1 shows a schematic diagram
of the experimental protocol. For comparison, age- and gender-
matched lean C57BL/6 J mice (n = 12) were used. Fenofibrate
and rosiglitazone (Avandia) were purchased from Sigma-Aldrich
and GlaxoSmithKline. DKO mice were treated with fenofibrate
(n = 14), rosiglitazone (n = 13) or placebo (n= 26) for 12 weeks
starting at the age of 12 weeks. Fenofibrate (50 mg kg21 day21)
and rosiglitazone (10 mg kg21 day21) were added to standard diet
(SD) containing 4% fat (Ssniff), placebo-treated mice received the
grinded chow only. Food and water were available ad libitum. Food
intake of the DKO mice was <5.7 g/day and was not affected by
the treatments. LDL-receptor deficient mice, on the C57BL/6 J
background, were fed ad libitum for a period of 12 weeks starting at
the age of 12 weeks with SD (n= 32) or with a high-fat diet (HFD)
containing 45% fat (n = 9). Food intake was 50% of that of DKO
mice, and was not different between SD- and HFD-fed mice. All
mice were sacrificed by Nembutal overdose at the age of 24 weeks.
Blood Values
After an overnight fast, blood was collected by puncturing the
vena cava. Plasma was obtained by centrifugation. Total cholesterol
and triglycerides were measured using standard enzymatic
colorimetric assays (Boehringer Mannheim). Glucose was mea-
sured with a glucometer (Menarini Diagnostics) and plasma insulin
with a mouse insulin enzyme-linked immunosorbent assay
(ELISA) (Mercodia). To convert from mg/dL to mM, we divided
glucose by 18 ( =molecular weight), triglycerides by 89 and total
cholesterol by 39. Insulin resistance was calculated by a homeo-
stasis model assessment of insulin resistance (HOMA-IR) = fasting
plasma insulin (mU/L) x fasting blood glucose (mM)/22.5. To
determine glucose tolerance, glucose was measured in samples
obtained by tail bleeding before and 15, 30, 60, 120 and 240
minutes after intraperitoneal administration of glucose (20%
glucose solution; 2 g/kg). Plasma adiponectin, TNFa and IL6
were measured with specific mouse ELISAs (R&D Systems)
[19,20].
Histological Analysis of Visceral Adipose Tissue and
Atherosclerosis
Ten mm-thick paraffin sections of adipose tissue were stained for
macrophages with an antibody against mouse Mac-3 antigen
(Pharmingen). Blinded analysis was performed on 12 fields of 3
sections from different levels (every 0.1 mm) of the visceral adipose
depot for each individual mouse with the Quantimet600 image
analyzer (Leica) and a light microscope with 206magnification.
Adipocyte size was determined as the mean adipocyte area
calculated by dividing the total adipocyte area by the total number
Figure 1. Experimental protocol. Twelve-week old DKO mice were
treated for 12 weeks with fenofibrate (50 mg kg21 day21) or with
rosiglitazone (10 mg kg21 day21) and were compared with placebo-
treated DKO and C57BL/6 J background mice. LDL-receptor deficient
(LDLR2/2) mice, on the C57BL/6 J background, were fed for a period of
12 weeks with standard diet (SD) or with a high-fat diet (HFD). The mice
were sacrificed at 24 weeks and total blood, the aortic arch, the
abdominal aorta, and visceral adipose tissue were collected.
doi:10.1371/journal.pone.0062253.g001
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of adipocytes for each mouse. The number of nuclei of Mac-3-
positive cells was averaged over 12 different fields, which were
most enriched with macrophages, and expressed as ratio to the
number of adipocytes. Dead/dying adipocytes were identified by
the presence of crown-like structures (CLS). CLS density was
obtained by counting the number of CLS in each section and
expressed as ratio to the number of adipocytes. Preparation of
sections of the aortic valves, determination of the extent of
atherosclerosis, and lipid (oil red O) and macrophage (Mac-3
Table 1. Primers used for qRT-PCR analysis.
Gene symbol Forward primer Reverse primer
Adipoq 59-CTCCTCATTTCTGTCTGTACGATTG-39 59-ACAGTAGCATCCTGAGCCCTTT-39
b-actin 59-ACGGCCAGGTCATCACTATTG-39 59-CACAGGATTCCATACCCAAGAAG-39
IL6 59-CTGTTGGGAGTGGTATCCTCTGT-39 59-CCACGGCCTTCCCTACTTC-39
Irak3 or Irak-m 59-TTTGCTAGGTTTTGGTTGTCAGAA-39 59-TGAGAAGCTAAACTGGAGCCAAT-39
Mcp1 or Ccl2 59-GCAGTTAACGCCCCACTCA-39 59-CAGCCTACTCATTGGGATCATCTT-39
Ppara 59-TCAGGGTACCACTACGGAGTTCA-39 59-CCGAATAGTTCGCCGAAAGA-39
Pparc 59-GCAGCTACTGCATGTGATCAAGA-39 59-GTCAGCGGGTGGGACTTTC-39
Tnfa 59-GGGAGGCCATTTGGGAACT-39 59-GCCACCACGCTCTTCTGTCTA-39
doi:10.1371/journal.pone.0062253.t001
Table 2. Blood, adipose tissue and plaque variables.
C57BL/6 J DKO ANOVA
Placebo Fenofibrate Rosiglitazone
A. Weight and blood variables
Weight (g) 28.161.0 61.860.8*** 58.761.1***/$ 54.961.0***/$$$/£ P,0.001
Total cholesterol (mM) 1.160.1 13.460.8*** 13.761.0*** 16.661.2***/$ P,0.001
Triglycerides (mM) 0.3060.24 3.160.3*** 2.460.3*** 1.960.3***/$ P,0.001
Glucose (mM) 4.260.2 8.260.5*** 7.060.5*** 4.960.3*/$$$/££ P,0.001
Insulin (mU/L) 74.364.4 213.3624.7*** 106.365.9***/$$$ 67.1616.3$$$ P,0.001
HOMA-IR 14.261.0 90.1615.1*** 31.262.2***/$$ 15.864.5$$$/£ P,0.001
AUC of IPGTT 35.160.4 87.664.9*** 74.864.2*** 50.861.2***/$$$/£££ P,0.001
TNFa (pg/mL) 22.461.2 29.761.9** 29.661.0*** 24.761.3$/££ P,0.01
IL6 (pg/mL) 17.960.6 29.362.4*** 21.162.3$ 14.661.7$$$/£ P,0.001
Adiponectin (mg/mL) 5.460.6 2.960.4** 1.160.2***/$$$ 16.260.7***/$$$/£££ P,0.001
B. Adipose tissue variables
Adipocyte size (x 103 mm3) 2.160.2 7.960.2*** 8.160.2*** 6.460.4***/$$/££ P,0.001
Macrophages/adipocyte 2.860.5 219.7610.8*** 122.5615.3***/$$$ 49.963.0***/$$$/£££ P,0.001
CLS (%) 0.0860.03 10.961.1*** 5.961.3***/$$ 1.360.2***/$$$/££ P,0.001
C. Plaque variables
Plaque volume (x 1023 mm3) ND 93.965.4 114.6610.1 60.3614.2$/££ P,0.01
Plaque macrophages (% of plaque area) ND 28.562.2 22.561.3$ 11.661.2$$$/£££ P,0.001
Plaque lipids (% of plaque area) ND 30.361.4 28.461.2 24.361.2$$/£ P,0.05
Data are means 6 SEM.
*P,0.05,
**P,0.01 and
***P,0.001 DKO compared with C57BL/6 J mice;
$
P,0.05,
$$P,0.01 and
$$$
P,0.001 PPAR agonist-treated compared with placebo-treated DKO mice;
£P,0.05,
££P,0.01 and
£££P,0.001 rosiglitazone-treated compared with fenofibrate-treated DKO mice.
Abbreviations: CLS, crown-like structures; ND, not detectable.
doi:10.1371/journal.pone.0062253.t002
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antibody) stainings were performed according to previously
described protocols [19,20].
Cell Culture
Bone marrow cells were isolated from 24-weeks-old C57BL/6 J,
DKO and IRAK32/2 mice. IRAK32/2 mice were kindly
provided by Dr. Flavell (Yale University) [8]. After euthanasia,
the mice were sprayed with 70% ethanol and the femurs were
dissected. Muscles connected to the bone were removed using
clean gauze, and the femurs were placed into a Petri dish
containing sterile PBS on ice. Both epiphyses were removed using
sterile scissors and the bones were flushed with a syringe with
DMEM containing 10% FBS (Gibco) to extrude bone marrow.
Single cell suspensions were prepared by passing the cells through
a 70-mm cell strainer. Cells were washed and incubated in
erythrocyte-lysis buffer (Miltenyi) for 10 minutes, according to the
Figure 2. Rosiglitazone and not fenofibrate treatment reduces macrophage accumulation and improves adiponectin expression in
visceral adipose tissue. (A) Representative Mac-3 staining of visceral adipose tissue of placebo-, fenofibrate- and rosiglitazone-treated DKO mice at
24 weeks. (B) Relative RNA levels of Tnfa, IL6, Mcp1 and Adipoq as determined by qRT-PCR. Data are means 6 SEM. Scale bar = 100 mm. *P,0.05 and
***P,0.001 DKO compared with C57BL/6 J mice; $$P,0.01 and $$$P,0.001 PPAR agonist-treated compared with placebo-treated DKO mice;
££P,0.01 and £££P,0.001 rosiglitazone-treated compared with fenofibrate-treated DKO mice.
doi:10.1371/journal.pone.0062253.g002
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manufacturer’s instructions. These fresh bone marrow cells were
differentiated to bone marrow-derived macrophages (BMDM)
[21], using L929 cell conditioned medium (LCCM) as a source of
granulocyte/macrophage colony stimulating factor [22]. The cells
derived from one femur were resuspended in 25 mL bone marrow
differentiation media, which is DMEM supplemented with 20%
FBS, 30% LCCM, 100 U/mL penicillin, 100 mg/mL streptomy-
cin, and 2 mM L-glutamine (Gibco). Cells were seeded in non-
tissue culture-treated 150 mm Petri dishes and incubated at 37uC
in a 5% CO2 atmosphere. Six days after seeding the cells, the
attached cells were washed and incubated overnight under normal
growth conditions. Then, cells were incubated with 50 mM
fenofibrate, 10 mM rosiglitazone, 5 mM GW9662 (Sigma-Aldrich)
and 1 or 10 mg/mL murine globular adiponectin (PeproTech) for
24 hours. Cell viability, as determined by trypan blue exclusion,
was .80%.
RNA Extraction and Gene Expression Analysis
Total RNA was extracted with TRIzol reagent (Invitrogen) and
purified on RNeasy Mini kit columns (Qiagen). First-strand cDNA
was generated from total RNA with the SuperScript VILO cDNA
synthesis kit (Invitrogen). Quantitative real-time PCR (qRT-PCR)
was performed using Fast SYBRGreen master mix according to
the supplier’s protocol (Applied Biosystems). Oligonucleotides
(Invitrogen) used as forward and reverse primers were designed
using the Primer Express software (Applied Biosystems) and are
summarized in Table 1. Data were normalized to the housekeep-
ing gene b-actin as previously described [20].
Western Blotting
Western blot analysis was performed with 20 mg of total protein.
Protein was electrophoresed through a 10–20% SDS-polyacryl-
amide gel (Bio-Rad) and transferred to a polyvinylidene difluoride
membrane (Millipore). Membranes were processed according to
standard Western blotting procedures. To detect protein levels,
membranes were incubated with primary antibodies against b-
actin (Cell Signaling Technology) and Irak3 (Rockland Immuno-
chemicals). The membranes were then incubated with horseradish
peroxidase-coupled secondary antibody (Santa Cruz Biotechnol-
ogy) and developed with SuperSignal chemiluminescent substrate
(Pierce). A PC-based image analysis program was used to quantify
the intensity of each band (Bio-1D).
Soluble Mcp1 Cytokine Levels
Conditioned medium was harvested after treatment of BMDM
and stored at 280uC. Soluble Mcp1 protein levels in the
conditioned medium were determined by ELISA according to
the manufacturer’s instructions (R&D Systems).
NFkB p50 DNA Binding Activity
NFkB p50 DNA binding activity was assessed on isolated
nuclear extracts of BMDM by ELISA using the TransAM NFkB
p50 transcription factor assay kit according to the manufacturer’s
protocol (Active Motif). Briefly, 10 mg of nuclear extract diluted in
complete lysis buffer was used in the p50 binding assay. The
samples were shaken for 1 hour at room temperature in 30 mL
binding buffer. After washing, anti-p50 antibody diluted 1:1000
was applied to the wells for 1 hour at room temperature. Specific
binding was estimated by spectrophotometry after incubation with
a horseradish peroxidaseconjugated antibody (1 hour at room
temperature, 1:1000 diluted) at 450 nm wave length.
Mitochondrial Reactive Oxygen Species Detection
To detect mitochondrial reactive oxygen species (mROS)
formation in treated BMDM, measurements of MitoSOX Red
(Invitrogen) fluorescence were performed by flow cytometry
(Becton, Dickinson and Company). Cells were incubated with
PBS containing 5 mM MitoSOX for 10 minutes at 37uC and 5%
CO2. The labeled cells were washed twice with PBS and then
suspended in warm PBS for analysis by flow cytometry.
Statistical Analysis
The Kruskal-Wallis nonparametric one-way ANOVA, followed
by the Dunn’s multiple comparisons test was used to compare
more than two independent samples. The unpaired t-test with
Welch’s correction test was used for the two-sample comparisons
(Graph Pad Prism version 5). Correlations were calculated using
the nonparametric Spearman’s correlation coefficient (rs). Non-
parametric tests were used because Gaussian distribution cannot
be expected in small sample size studies as performed in this
article. The area under the curve of the intraperitoneal glucose
tolerance test (AUC of IPGTT) was calculated in Graph Pad
Prism version 5. A probability value of P,0.05 was considered
statistically significant.
Results
Rosiglitazone in Contrast to Fenofibrate Decreases
Systemic Inflammation and Restores Insulin Sensitivity
Body weight, plasma total cholesterol and triglycerides were
significantly higher in placebo-treated DKO mice compared with
lean C57BL/6 J background mice. Glucose and insulin levels, and
thus the HOMA-IR index were similarly elevated. Glucose
tolerance as measured by AUC of IPGTT was increased. The
higher levels of TNFa and IL6, and the lower adiponectin levels
indicated systemic inflammation (Table 2A). Both fenofibrate and
rosiglitazone decreased weight and insulin levels. Interestingly,
only rosiglitazone treatment reduced glucose levels resulting in
a decrease in HOMA-IR and a partial normalization of glucose
tolerance. Systemic inflammation was only decreased after
rosiglitazone treatment evidenced by lower levels of TNFa and
IL6 and increased adiponectin levels. Both treatments had almost
no effect on total cholesterol and triglycerides (Table 2A).
Table 3. Ppara and Pparc expressions in visceral adipose and
aortic tissues of PPAR agonist-treated DKO mice.
DKO ANOVA
Placebo Fenofibrate Rosiglitazone
A. Visceral adipose tissue
Ppara 0.2360.02*** 0.3760.04***/$$ 1.8360.17***/$$$/£££ P,0.001
Pparc 0.2160.01*** 0.3360.03***/$$ 0.4360.02***/$$$/£ P,0.001
B. Abdominal aorta
Ppara 0.5860.05* 0.5760.05* 3.3360.39***/$$$/£££ P,0.001
Pparc 0.6760.07* 1.0060.05$$$ 1.1160.09$$$ P,0.001
Data are means 6 SEM.
*P,0.05 and
***P,0.001 DKO compared with C57BL/6 J mice;
$$
P,0.01 and
$$$
P,0.001 PPAR agonist-treated compared with placebo-treated DKO mice;
£P,0.05 and
£££P,0.001 rosiglitazone-treated compared with fenofibrate-treated DKO mice.
doi:10.1371/journal.pone.0062253.t003
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Rosiglitazone and not Fenofibrate Improves Adipocyte
Function by Decreasing Macrophage Accumulation
Figure 2A shows representative sections of visceral adipose
tissue stained for macrophages of placebo-, fenofibrate-, and
rosiglitazone-treated DKO mice. The adipocyte size, number of
macrophages and CLS, which indicates necrotic adipocytes
surrounded by phagocytes, were increased in DKO mice
compared with lean C57BL/6 J mice (Table 2B). Only rosiglita-
zone decreased the adipocyte size. Both treatments, but rosiglita-
zone more than fenofibrate, reduced the number of macrophages
and CLS in adipose tissue of DKOmice (Table 2B and Figure 2A).
Furthermore, rosiglitazone decreased Tnfa, IL6 and Mcp1 expres-
sions, and increased the expression of Adipoq (Figure 2B).
Rosiglitazone treatment also resulted in a greater increase in
Ppara than fenofibrate treatment; differences in Pparc were less
pronounced (Table 3A).
Figure 3. Rosiglitazone and not fenofibrate treatment decreases atherogenesis in obese, insulin resistant mice. (A) Representative
Mac-3 staining of aortic sinus plaques of placebo-, fenofibrate- and rosiglitazone-treated DKO mice at 24 weeks. (B) Gene expression in the aorta was
analyzed by measuring relative RNA levels using qRT-PCR for Tnfa, IL6,Mcp1 and Irak3. Data are means6 SEM. Scale bar = 500 mm. *P,0.05, **P,0.01
and ***P,0.001 DKO compared with C57BL/6 J mice; $$P,0.01 and $$$P,0.001 PPAR agonist-treated compared with placebo-treated DKO mice;
£P,0.05, ££P,0.01 and £££P,0.001 rosiglitazone-treated compared with fenofibrate-treated DKO mice.
doi:10.1371/journal.pone.0062253.g003
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Figure 4. Adiponectin-induced Irak3 plays an important role in rosiglitazone-mediated decrease of Mcp1. (A) Soluble Mcp1 protein
levels in DKO BMDM exposed to 50 mM fenofibrate, 10 mM rosiglitazone or 5 mM GW9662 for 24 hours as determined by ELISA. Data are means 6
SEM; n = 16 from three different mice. $$P,0.01 compared with fenofibrate-treated BMDM. (B) Irak3 RNA and protein levels of DKO BMDM exposed to
1 or 10 mg/mL globular adiponectin for 24 hours as determined by qRT-PCR and Western blotting. Data are means 6 SEM; n= 6. ***P,0.001
compared with DKO BMDM; $P,0.05 and $$P,0.01 compared with DKO BMDM exposed to 1 mg/mL globular adiponectin. (C) Soluble Mcp1 protein
PPAR Agonists in Atherosclerosis
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Rosiglitazone and not Fenofibrate Reduces
Atherosclerotic Plaque Volume and Macrophage Content
by Decreasing Macrophage Accumulation
Figure 3A shows representative sections of atherosclerotic
lesions stained for macrophages of placebo-, fenofibrate-, and
rosiglitazone-treated DKO mice. Fenofibrate had no effect on
overall plaque volume. In contrast, rosiglitazone decreased plaque
volume by inhibiting macrophage and lipid deposition (Table 2C).
In addition, rosiglitazone treatment decreased Tnfa, IL6 and Mcp1
expressions in extracts of abdominal aorta. Furthermore, Irak3
expression was increased after rosiglitazone treatment (Figure 3B).
Irak3 in the aorta correlated positively with circulating adiponectin
levels (rs = 0.41, P,0.01) and negatively with Tnfa (rs =20.43,
P,0.01), IL6 (rs =20.35, P,0.05) and Mcp1 (rs =20.46,
P,0.001). The expression of Adipoq in aortic extracts, 2.1-fold
decreased in DKO compared with C57BL/6 J mice (P,0.01),
increased more after rosiglitazone treatment (1.8-fold vs. DKO,
P,0.01; 1.4-fold vs. fenofibrate treatment, P,0.05) than fenofi-
brate treatment (1.2-fold vs. DKO, P,0.05). Rosiglitazone
treatment also resulted in a greater increase in Ppara than
fenofibrate treatment; differences in Pparc were not significant
(Table 3B).
Irak3 Induction Dependent on High Adiponectin is
Required for the Decreased Expression of Mcp1 after
Rosiglitazone Treatment
We investigated the direct effect of fenofibrate, rosiglitazone,
and PPARc antagonist (GW9662) treatment on BMDM from
DKO mice to elucidate the observed differences between PPAR
treatments. Fenofibrate tended to increase Mcp1 protein.
Rosiglitazone did not decrease Mcp1 protein and addition of the
PPARc antagonist did not increase Mcp1 protein. In aggregate,
we did not observe a direct inhibitory effect of PPAR agonists on
levels (n = 18 from three different mice), NFkB p50 DNA binding activity (n = 8 from two different mice) and mROS production (n = 6) in IRAK32/2
BMDM exposed to 50 mM fenofibrate or 10 mM rosiglitazone for 24 hours as determined by ELISA and flow cytometry. Data are means 6 SEM.
*P,0.05, **P,0.01 and ***P,0.001 compared with C57BL/6 J BMDM; $P,0.05 and $$$P,0.001 compared with IRAK32/2 BMDM; £££P,0.001
compared with fenofibrate-treated BMDM. Abbreviations: BMDM, bone marrow-derived macrophages; mROS, mitochondrial reactive oxygen species.
doi:10.1371/journal.pone.0062253.g004
Figure 5. HFD-induced weight gain is associated with dyslipidemia, insulin resistance and hyperleptinemia in the presence of high
blood adiponectin. Data are means 6 SEM. **P,0.01 and ***P,0.001 HFD-fed compared with SD-fed LDL-receptor deficient mice. Abbreviations:
HFD, high fat diet; SD, standard diet.
doi:10.1371/journal.pone.0062253.g005
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Mcp1 protein secretion (average Mcp1 concentration in DKO
BMDM: 31.861.6 pg/mL) (Figure 4A).
However, we have previously shown that there is a causal
relation between variable globular adiponectin levels and IRAK3
expression in blood monocytes of obese patients [10]. Because we
found that rosiglitazone increased adiponectin more than fenofi-
brate, we determined the effect of low (as in untreated and
fenofibrate-treated DKO mice) and high (as in rosiglitazone-
treated DKO mice) globular adiponectin concentrations on the
Irak3 expression in BMDM. Indeed, exposure to 10 mg/mL
globular adiponectin increased the Irak3 expression (RNA and
protein) in comparison with exposure to 1 mg/mL globular
adiponectin (Figure 4B).
Then, we investigated if Irak3 deletion had an effect on Mcp1
expression. The deletion of Irak3 in BMDM (IRAK32/2 BMDM)
was characterized by activation of the canonical NFkB signaling
pathway as determined by NFkB p50 DNA binding activity. This
resulted in a 2.2-fold increase in Mcp1 protein secretion compared
with control cells (185.5624.5 vs. 84.567.3 pg/mL, P,0.001).
Rosiglitazone treatment did not decrease the elevated Mcp1
secretion in IRAK32/2 BMDM and fenofibrate even increased
the production of Mcp1, independently from NFkB p50 DNA
binding activity. However, the observed increase in Mcp1 after
fenofibrate treatment was associated with increased mROS
production (Figure 4C).
Lower Adipoq and Irak3 Expressions are Associated with
M1 Macrophages and Accelerated Atherosclerosis in
High-fat Insulin Resistant Mice
Body weight, plasma total cholesterol and triglycerides were
significantly higher in HFD-fed LDL-receptor deficient mice
compared with SD-fed mice, with C57BL/6 J background.
Glucose tolerance, as measured by AUC of IPGTT and
HOMA-IR index was elevated. In contrast to DKO, HFD-fed
LDL-receptor deficient mice had increased blood levels of
adiponectin. In addition, their leptin levels were elevated (Figure 5).
Figure 6 shows accelerated atherosclerosis in aortic arch of high-
fat insulin resistant mice, due to increased macrophage content.
Aortic Pparc, Adipoq and Irak3 expressions were decreased, whereas
Mcp1 expression was increased. Ppara expression was not
significantly decreased in aorta of HFD-fed mice (data not shown).
Increased aortic inflammation in HFD-fed mice was further
evidenced by a 1.6-fold increase in Tnfa (P,0.01) and a 7.2-fold
increase in IL6 (P,0.001).
Figure 6. HFD increases atherogenesis in insulin resistant mice. Plaque volume was determined by measuring lipid (oil red O)-stained
surfaces in subsequent sections; macrophages were stained with anti-Mac-3 antibody. Gene expression in the aorta was analyzed by measuring
relative RNA levels using qRT-PCR for Pparc, Mcp1, Irak3 and Adipoq. Data are means 6 SEM. **P,0.01 and ***P,0.001 HFD-fed compared with SD-
fed LDL-receptor deficient mice. Abbreviations: HFD, high fat diet; SD, standard diet.
doi:10.1371/journal.pone.0062253.g006
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Discussion
Previous studies have shown that treatment with PPAR agonists
could prevent vascular inflammation, atherosclerosis and the
development of cardiovascular disease [23–25]. In the present
study, we showed that rosiglitazone, a PPARc agonist, could
reduce obesity-induced systemic inflammation, insulin resistance,
macrophage accumulation and atherosclerotic plaque formation.
In contrast, treatment with fenofibrate, a PPARa agonist, did not
reduce systemic inflammation or plaque formation.
PPARc agonists not only increase peripheral insulin sensitivity
but also cause dramatic decreases in systemic inflammation. In
obese diabetic patients, rosiglitazone has been shown to decrease
circulating C-reactive protein and IL6 levels [26,27]. Rosiglita-
zone, but not fenofibrate, also increased adiponectin in our DKO
mice. Previously, we demonstrated a relation between adiponectin
and Pparc in the heart, insulin sensitivity, and cardiac function,
independent of cholesterol and triglycerides [28]. PPARc increases
adiponectin through a PPAR-responsive element in the adipo-
nectin promoter in adipocytes [29,30]. The increase in adipo-
nectin may explain the more pronounced increase in Ppara
expression in adipose and aortic tissues [31,32]. Our study also
confirmed that adiponectin is essential for the indirect vascular
protective effect of rosiglitazone [33–35] at least partially through
upregulation of Irak3 in plaque macrophages. Indeed, we
observed that high levels of adiponectin increases the expression
of Irak3 in BMDM, which at its turn is necessary for the indirect
vascular protective effect of rosiglitazone on macrophages as
evidenced by the elevated Mcp1 protein secretion in IRAK32/2
BMDM in vitro. Several recent studies have demonstrated that
IRAK3 regulates critical aspects of innate immunity, including the
development of endotoxin tolerance after adiponectin exposure.
Adiponectin induces IRAK3 expression through ERK1/2 and
PI3K/Akt signaling cascades [9]. Furthermore, IRAK3 is an
important regulator by which tumor-associated macrophages
mimic the phenotype of alternatively activated (M2) macrophages
[36]. IRAK3 also attenuates post-infarction remodeling by
protecting the heart from uncontrolled inflammation and excessive
matrix degradation [37]. A surprising finding was that aortic
expression of Irak3 in HFD-fed insulin resistant mice was observed
in association with increased blood levels of adiponectin. But aortic
Adipoq expression was decreased in association with lower Pparc
expression, suggesting that local expression in macrophages is
more relevant than systemic expression by adipose tissues. This is
in agreement with the observation that rosiglitazone inhibited
monocyte/macrophage adhesion through de novo adiponectin
production in human monocytes [38]. Also, HFD-fed mice had
elevated levels of leptin that together with high insulin induces
inflammation [39,40]. Previously, it has been suggested that
PPARc guarantees a balanced and adequate production of
secretion from adipose tissue of adipocytokines such as adiponectin
and leptin, which are important mediators of insulin action in
peripheral tissues [41]. Our data in HFD-fed mice indicate that
imbalanced production does not necessarily imply high leptin and
low adiponectin. Elevated leptin, even in presence of high
adiponectin, is sufficient to generate an inflammatory response.
Similar to PPARc agonists, PPARa agonists, like fenofibrate,
have also demonstrated anti-inflammatory properties in addition
to their other beneficial effects on metabolism [15,42]. However,
in our study, fenofibrate treatment had no effect on systemic
inflammatory markers, and did not increase adiponectin levels and
Irak3 expression and did not decrease the expression of Mcp1. In
addition, exposure of IRAK32/2 BMDM to fenofibrate resulted
in an increased secretion of Mcp1 protein in vitro. The different
Mcp1 secretion after rosiglitazone and fenofibrate treatment is
independent of activation of the canonical NFkB signaling
pathway but is possibly due to the increased ROS production
observed after fenofibrate treatment. Indeed, it has been suggested
that ROS production is involved in the regulation of Mcp1
expression [43]. However, we have to take into account that
a mouse model is not the best model to evaluate PPARa selective
compounds for their anti-atherosclerotic efficacy because in
humans fenofibrate also influences lipid metabolism through
modulation of cholesteryl ester transfer protein [44]. In diet-fed
hamsters, the anti-atherosclerotic efficacy of fenofibrate occurred
primarily via reductions in pro-atherogenic lipoproteins. However,
Figure 7. Adiponectin and macrophage-associated Irak3 are indispensable molecules in the anti-atherosclerotic properties of PPAR
agonists. The schematic draw demonstrates the anti-atherosclerotic properties of the PPARc agonist rosiglitazone. Treatment with rosiglitazone
improves the adipocyte function characterized by a decrease in adipocyte size, a reduction in adipose tissue macrophages and an increased
expression of anti-inflammatory adiponectin. The increase in blood adiponectin and de novo adiponectin production in atherosclerotic lesions is
necessary for the upregulation of Irak3 in plaque macrophages, which is crucial for the indirect rosiglitazone-mediated decrease in Mcp1 secretion.
Abbreviations: Mw, macrophages; ROS, reactive oxygen species.
doi:10.1371/journal.pone.0062253.g007
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these hamsters were not obese and did not display insulin
resistance [45]. Furthermore, the dosages of fenofibrate and
rosiglitazone were approximately 2 and 6 times higher than the
maximum recommended daily dose in humans. However, in this
study, fenofibrate and rosiglitazone were used as experimental
tools to identify underlying mechanisms that could apply to
patients treated with the drug. Finally, our data are in agreement
with previous data of Duez et al. showing that fenofibrate did not
reduce atherosclerotic lesion area in the aortic sinus of ApoE
deficient mice [46]. However, they found a reduction of
cholesterol content in descending aortas of treated mice, an effect
that was more pronounced in older mice exhibiting more
advanced lesions. Unfortunately, in our study we did not measure
cholesterol levels in the descending aorta. Interestingly, fenofibrate
reduced lesions in the aortic sinus of ApoE deficient mice
overexpressing human apolipoprotein-A1 [46].
Conclusions
In summary, we found that rosiglitazone in contrast to
fenofibrate improves insulin sensitivity and adiponectin levels
and inhibits inflammation and atherosclerotic plaque formation by
reducing M1 macrophage accumulation in the vascular wall. In
addition, the adiponectin-dependent upregulation of Irak3 in
macrophages is necessary for the reduction in Mcp1 secretion, and
thus switch from M1 to M2. HFD-induced increase in leptin
causes inflammation associated with decreased Irak3 expression in
association with accelerated atherosclerosis, even in presence of
high blood levels of adiponectin but decreased plaque expression
of Adipoq. In summary, we showed that Irak3 as an inhibitor of
NFkB and ROS production is required for the protective action of
particularly the PPARc agonist (Figure 7).
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